The question the studies were asking
Growth-hormone secretagogues were not invented for biohacking. They were developed as an alternative to administering growth hormone itself, on the reasoning that prompting the pituitary to release its own hormone preserves the body's feedback regulation in a way that exogenous administration does not.
The problem with the early compounds was selectivity. GHRP-6 and GHRP-2 reliably raised growth hormone, but they also raised cortisol, raised prolactin, and produced a marked increase in appetite. Those effects limited their usefulness.
What ipamorelin showed
Ipamorelin was developed specifically to address that. In controlled studies, it produced dose-dependent growth-hormone release while showing minimal effect on cortisol and prolactin, and — notably — without the appetite increase that characterised the earlier ghrelin-receptor agonists.
That selectivity profile is the actual finding, and it is well supported. It is also the reason ipamorelin became the default choice in this category.
Why the pulse shape matters
Growth hormone is released in bursts, predominantly during deep sleep. A secretagogue that produces a discrete pulse — rising and falling over a couple of hours — mimics that pattern. A compound with a very long half-life flattens the curve instead, producing sustained elevation.
Which is preferable is an open question. Sustained elevation is closer to what exogenous growth-hormone therapy does; pulsatile release is closer to normal physiology. The conventional argument in favour of pulsatile is that it preserves feedback regulation and avoids continuous receptor stimulation. That argument is physiologically reasonable and has not been tested head to head in a trial.
What was not measured
The studies establishing ipamorelin's selectivity measured hormones. They measured growth hormone, cortisol, prolactin, appetite and tolerability. They did not measure body composition, recovery, sleep quality or any longevity endpoint over a meaningful period.
That gap is the whole story of this compound. The endocrine effect is documented. Everything people actually take it for is extrapolated from what growth hormone does in other contexts.
The studies answer "does it raise growth hormone selectively?" They do not answer "does that produce a benefit?"
The practical implications
Two findings follow directly from the mechanism and are worth knowing regardless of the outcome question:
Fasting matters. Circulating glucose and insulin suppress growth-hormone release. A dose taken after a meal produces a smaller pulse. This is why the convention of dosing on an empty stomach exists, and it reflects physiology rather than habit.
Timing matters. Placing the dose before sleep aligns the induced pulse with the natural nocturnal one. Dosing at midnight after a late meal is not equivalent to dosing before sleep on an empty stomach.
Where the risk sits
Raising growth hormone raises IGF-1, and IGF-1 promotes cell proliferation and influences glucose metabolism. The practical monitoring implication is fasting glucose — worsening insulin sensitivity is the effect most likely to show up first, and it is measurable. The population-level caution is anyone with active malignancy, proliferative retinopathy or untreated pituitary disease, for whom elevated IGF-1 is a mechanistic concern rather than a theoretical one.